Retisert implant in sympathetic ophthalmia

Article

The fluocinolone acetonide (Retisert; Bausch & Lomb) surgical implant can prevent blindness in cases of sympathetic ophthalmia (SO), according to research at the University of Iowa, US.

The fluocinolone acetonide (Retisert; Bausch & Lomb) surgical implant can prevent blindness in cases of sympathetic ophthalmia (SO), according to research at the University of Iowa, US.

James C. Folk, MD and colleagues conducted a retrospective non-comparative case study of eight SO patients implanted with the Retisert and followed-up for up to one year.

By the final follow-up, vision had been maintained or had improved in all patients. All patients reduced their dependence on anti-inflammatory medication significantly, although two later recommenced oral immunosuppressive treatment.

The researchers concluded that, as use of the implant is effective at controlling inflammation, it can prevent the need for life-long systemic immunosuppression in SO patients.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.